InvestorsHub Logo
Followers 110
Posts 6480
Boards Moderated 0
Alias Born 05/01/2003

Re: None

Monday, 04/18/2011 9:20:47 AM

Monday, April 18, 2011 9:20:47 AM

Post# of 92948
ACT granted CHA Biotech an Exclusive License to use and commercialize the Single Blastomere Technology in South Korea. Total payment to ACT for Exclusive License was $300,000.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.